Introduction
In recent decades, with the increasing use of intravascular iodinate contrast media for diagnostic and therapeutic purposes, contrast induced nephropathy (CIN) has become one of the more common serious complications, in particular in patients undergoing percutaneous coronary invasive procedures (PCIP) (1) . In clinical practice, it is important to estimate the individual risk of developing CIN and, with regard to this, a score capable of predicting this complication has been proposed (2) . Considering the classical biomarkers of renal function, serum creatinine is unfortunately poorly sensitive, being greatly influenced by many renal and nonrenal factors, such as: changes in muscle mass and tubular secretion, race, age, gender, total body volume (3) and therefore it does not help in distinguishing between the mechanisms of nephrotoxicity. Moreover, variations in creatinine values are not useful for early detection of CIN since increases in this parameter are often observed 48-72 hours after contrast medium administration.
Recent research has been addressed at finding new, more sensitive, biomarkers for the earlier diagnosis of acute kidney injury. Among them, Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C (CysC) have been explored, but conflicting results are reported regarding their role in the early detection of CIN (4) (5) (6) (7) .
The aim of this study was to test the association of both baseline values and postprocedural variations in either urinary and serum NGAL as well as serum CysC with CIN occurrence, after PCIP compared to serum creatinine and the estimated glomerular filtration rate (eGFR).
Materials and methods
From February to August 2010 we prospectively enrolled 43 patients who were admitted to our Cardiac Step-Down Unit and submitted to PCIP, either for stable coronary artery disease such as stable angina and inducible myocardial ischemia, or for acute coronary syndromes. Exclusion criteria were the positivity of the urine culture sample and eGFR <60 ml/min/1.73 m 2 . At admission and during hospitalization, the following laboratory parameters were measured in a fasting blood sample: hemoglobin (g/dL), troponin I (ng/ ml), leukocyte count (N/mm 3 ), neutrophil count (N/mm 3 ), serum creatinine (mg/dL), serum CysC (ng/ml)(on admission and 4 hours after PCI), fibrinogen (mg/dl), C-reactive protein (CRP) (mg/L).
We also measured urinary and serum NGAL (ng/ml) (on admission and 4 hours after PCI); values of urinary NGAL were also adjusted for urinary creatinine values by calculating the urinary NGAL to urine creatinine ratio. For NGAL assays fresh urine and EDTA samples were collected from all patients. EDTA samples were immediately centrifuged and aliquoted. All samples were kept at -80°C until assayed in the following weeks. Serum NGAL was measured with the Triage NGAL Test (Biosite-Inverness Medical, Waltham, MA), which is a pointof-care-immunoassay for the quantitative determination of NGAL in EDTA anticoagulated whole blood or serum specimen. Urine NGAL was assessed with an automated immunoassay (Abbott Park, IL) on the Architect platform. The Architect NGAL assay is a non-competitive two-site sandwich immunoassay that utilizes two mouse antibodies, recognizing distinct NGAL epitopes. For CysC measurement, serum blood samples were kept at -20°C until assayed in the following weeks. Serum CysC was assayed by means of a nephelometric method (nephelometry Dako; IMMAGE ® 800, Beckman Coulter, Inc. Fullerton, CA). All tests were performed by a well trained laboratory technician according to the manufacturers' instructions. We calculated eGFR (ml/ min/1.73 m 2 ) with the MDRD formula. On admission, a urine culture was taken for each patient.
In agreement with previous studies, CIN was defined as an increase in serum creatinine by >25% or >0.5 mg/dl over baseline values, 48 hours after PCIP (2). The study protocol was in accordance with the Helsinki Declaration of 1975, as revised in 1983. Informed consent was obtained from all patients before enrollment. Our study had a prospective design. All data were prospectively collected in a dedicated database and analyzed. ; this cutoff value for neutrophils showed association with higher leukocyte count and higher values of erythrocyte sedimentation rate or C reactive protein, confirming an inflammatory pattern. This has been previously reported in the literature to be associated with a higher prevalence of respiratory symptoms, such as bronchitis and persistent cough (8) . To evaluate differences of variables analyzed between baseline and post-contrast medium administration values, the nonparametric Wilcoxon rank sum test for paired data was used. Correlations among biomarkers of renal damage and other clinical and laboratory parameters were assessed using the Pearson correlation test, when analyzing variables normally distributed, or the Spearman rank correlation test for variables not normally distributed.
Statistical analysis
To determine the best baseline CysC threshold associated with CIN occurrence, receiving operating characteristics (ROC) analysis was performed and the area under the ROC curves (AUROC) was calculated; the optimal cut off point was chosen among the coordinates of the ROC curves at the point that gave a balanced weight between sensitivity and specificity. A p value <0.05 was considered statistically significant.
Results
Our population was composed of 59 patients, of which 16 were excluded due to the positivity of their urine culture sample, or for eGFR <60 ml/min/1.73 m 2 . In Table  1 the main clinical and angiographic characteristics of the 43 patients included in our analysis are presented. Out of them, 7 patients (16%) developed CIN. Patients who developed CIN were significantly older than those who did not.
In Table 2 laboratory data of the patients analyzed in relation to CIN occurrence are reported. Patients who developed CIN had significantly higher discharge serum creatinine values, lower eGFR values at serum peak creatinine and higher serum CysC values, either before and after PCIP. There was no significant difference in serum CysC between the values measured before and those assessed after PCIP in either of the two subgroups analyzed. Moreover, there was no significant difference between the two groups of patients in serum NGAL before and after PICP, or in urinary NGAL before and after PCIP, even after adjustment for urinary creatinine values. Patients who developed CIN underwent in a significantly higher percentage bare-metal stent implantation. In patients who developed CIN no significant variations between baseline and post-PCIP values in serum CysC, urinary and serum NGAL, or urinary NGAL/creatinine ratio were observed.
As depicted in Table 3 , patients (n=14) with a positive inflammatory pattern (neutrophil count higher than 4200/mm 3 ) had significantly higher values of urinary NGAL, either pre-PCIP and post-PCIP, even when adjusted for urinary creatinine values, as well as higher values of pre-PCI serum NGAL. Moreover, using the Pearson correlation test, a significant correlation was found between age and both serum CysC pre-PCIP (r=0.62; p=0.000) and serum CysC post-PCIP (r=0.58; p=0.000), between eGFR and both serum creatinine at admission (r=-0.71; p=0.000) and serum CysC pre-PCIP (r=-0.45; p=0.003), as well as between serum CysC pre-PCIP and creatinine at the peak (r=0.47; p=0.001) and at discharge (r=0.39; p=0.01).
The Spearman rank correlation test showed a significant correlation between the serum CysC pre-PCIP and urinary NGAL post-PCIP/creatinine ratio (r=0.32; p=0.035), and urinary NGAL post-PCIP (r=0.43; p=0.004) in the overall population of patients, and a mild but significant correlation between serum creatinine at discharge and NGAL post-PCIP/creatinine ratio (r=-0.30; p=0.048).
The results from the ROC curve showed that the optimal cut-off value of serum CysC for CIN diagnosis was 1.18 ng/ml. For this value, sensitivity was 0.857 and specificity 0.778 (AUROC=0.863; p=0.003). Finally, by univariate analysis using this latter cutoff, CysC values higher than 1.18 ng/mL resulted in a significant association with CIN occurrence (p=0.003).
Discussion
The main finding of our investigation was that in patients undergoing PCIP, high values of serum CysC, even at baseline, may be considered a useful marker associated with CIN occurrence, earlier than creatinine and eGFR variations. Furthermore, in our series, neither serum nor urinary NGAL showed any significant association with the development of CIN. Data about these novel biomarkers as predictors of acute kidney injury after PCIP are inconsistent and contradictory.
It is well known that CysC, a protease inhibitor, is freely filtered in normal circumstances by the glomeruli and completely reabsorbed in the proximal tubule. In the absence of tubular dysfunction, its serum levels reflect glomerular filtration; therefore it could be used as a convenient measure of glomerular filtration rate (9). CysC is not affected by storage conditions or interfering substances: some limitations of the serum creatinine level, including the effects of gender, body muscle mass and diet, do not significantly influence serum CysC levels. Elevated urine CysC levels may also indicate tubular epithelial damage, and have been proposed as an additional urine biomarker for acute kidney injury (10) . In particular, in intensive care settings, serum CysC has been able to detect acute kidney injury earlier and has been more sensitive than serum creatinine in detecting minor glomerular filtration rate reductions (11) , even in patients with sepsis (12) .
This early increase in serum CysC following a kidney injury is also reported in studies that investigated renal toxicity after contrast medium administration (4) (5) (6) (13) (14) (15) (16) (17) (18) . In all these investigations the peak of serum CysC was significantly associated with the development of CIN occurring 24-48 hours after PCIP. Moreover, in agreement with previous studies (12, 19, 20) , our investigation demonstrated that high baseline values of CysC are associated with CIN occurrence.
On the other hand, in the study by Rubichini and colleagues (7), variations in serum creatinine from the baseline offered better diagnostic accuracy for predicting CIN at an earlier stage than similar changes in CysC in patients with known mild or moderate chronic renal disease, undergoing PCI. However, in our investigation we evaluated patients with eGFR >60 ml/min/1.73 m 2 . Although our study strengthens the role of baseline CysC as a biomarker early associated with CIN occurrence in the setting of PCIP, as already reported (20) , no significant variation in CysC in the subgroup of patients developing CIN was observed after contrast medium administration. Interestingly, patients who developed CIN were significantly older and a significant correlation was found between CysC and patient age. Moreover, CysC pre-PCIP results were significantly correlated with values of urinary NGAL assessed after PCIP, even after adjustment for urinary creatinine values, as well as with creatinine at the peak and at discharge, confirming that even values of CysC at baseline may be associated with CIN since they correlate with later changes in creatinine, as well as in other markers of acute kidney injury, assessed after contrast medium administration.
Furthermore, in our series we also evaluated both urinary and serum NGAL values as possible helpful markers for CIN development. NGAL, a small protein of the lipocalin superfamily, expressed by a wide variety of tissues, is primarily synthesized in the ascending loop of Henle and in the collecting ducts. It acts as a growth and differentiating factor in renal epithelium, by limiting apoptosis and maintaining the tubular structure. Raised NGAL concentrations might represent a physiological or adaptative response to injury (21) , since it is has a nephroprotective effect in the proximal tubule. NGAL is rapidly upregulated in kidneys after an ischemic or nephrotoxic insult, and limits parenchymal damage (22) . For these reasons NGAL has been explored as a biomarker of acute and chronic kidney injury. Both serum and urinary NGAL concentrations have been shown to be good predictors of CIN development in previous several studies (4, 23) . Bachorzewska-Gajewska and colleagues (4) demonstrated in patients with stable angina that NGAL levels were significantly higher in patients with CIN from 2 hours after PCI (serum, p<0.005) and 4 hours (urinary, p<0.005), respectively. In another study (23) , a significant increase in both serum and urinary NGAL occurred in patients developing CIN two hours after contrast medium administration. However, although NGAL is considered a promising biomarker for early diagnosis of acute tubular necrosis (24) , serum NGAL is already elevated in patients with chronic renal disease, and it rises 6-times less than urinary NGAL in cases of renal injury (7) .
Furthermore, urinary NGAL remains low in patients with pre-renal azotemia or normal renal function (25) . Urinary NGAL is of interest after cardiac surgery; in this setting its values resulted in a significant association for early diagnosis of acute kidney injury (26, 27) . Haase et al. (28) analyzed data from 191 patients in 3 studies and found that when urinary NGAL is measured within 6 hours after contrast medium administration, it has better sensitivity than serum creatinine alone for acute kidney injury detection. Moreover, recent studies and a meta-analysis have demonstrated the role of serum and urinary NGAL in the prediction of CIN (15, 16, (29) (30) (31) (32) (33) (34) (35) (36) and, although this biomarker has also been reported to have a low sensitivity in predicting CIN in specific settings, such as ACS (37), a previous study also suggested that it can also predict the severity of CIN (38) .
Despite the positive results of these biomarkers in predicting CIN in the above mentioned studies, in our investigation we did not detect any significant association between baseline serum and urinary NGAL values and their 4 hour variations after contrast medium administration and CIN occurrence. Our results may have several explanations: first of all, our analysis included patients with acute coronary syndromes, a condition in which inflammation is present, so that in these patients raised serum NGAL levels may reflect the degree of inflammatory status (39) due to the acute cardiac disease more than that of acute kidney injury. Accordingly, in our series, we observed that baseline values of either serum and urinary NGAL were significantly higher in patients with a higher neutrophil count, making the post-PCIP variations less significant. On the contrary, we believe that this biomarker could be useful for CIN detection in patients with stable coronary artery disease, as previously reported (4, 23) , without other causes of acute inflammation, such as urinary tract infections or acute exacerbations of obstructive pulmonary disease, which is not the typical population of Cardiac Step Down or Intensive Care Units.
Though strong evidence has been provided for the use of NGAL in a variety of settings, its route into clinical management protocols is still under evaluation (40) . Moreover, our results are in agreement with those of a recent review reporting the "rise and fall" of NGAL in acute kidney injury (41) . In fact, authors conclude that since a rise in NGAL was first suggested more than a decade ago as a potential biomarker of early acute injury, the idea of this marker as a troponin for the kidneys has been relinquished because it also increases unpredictably during other chronic and acute inflammatory conditions frequently encountered in intensive care settings (41) . The availability of assays measuring kidney-specific NGAL will improve the chance of detecting patients at risk of acute kidney injury.
Limitations of study
Our study has also several limitations: first of all, a limited number of patients investigated; and second, the heterogeneity of coronary artery disease patients, for whom PCIP were performed.
Conclusion
In conclusion, our investigation demonstrates that in a population of patients admitted to a Cardiac Step-Down Unit and submitted to PCIP, neither baseline serum and urinary NGAL nor their variations after PCIP are useful for an early diagnosis of CIN. In particular, the use of this biomarker to detect CIN is limited in ACS patients, due to its inability at discriminating between inflammatory injury associated with CIN development or with the acute cardiac disease per se. On the contrary, in our observation, CysC resulted in an association with CIN occurrence earlier than creatinine and eGFR variations, even though further research in this area is needed, given the limitations of this study. Authors' contributions: Conception and design: EC and CG; Acquisition, analysis and interpretation of data: GA and AT; Drafting the article: MGD; Revising it critically for important intellectual content: AC and EG; Approved final version of the manuscript: EC, CG and AC.
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Contrast induced nephropathy (CIN) is a common and serious complication in patients undergoing percutaneous coronary invasive procedures (PCIP)
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